ZS (-6%) posting rev, eps and billings upside vs street but billings missed buyside bogeys and investors unhappy with lack of full year raise to billings guide.
F1Q: revenue/EPS of $497m/$$0.67 vs. Street at $473m/$0.49.
Billings of $457m +34% came in above the Street at $442m but below buyside at ~465M
Keep reading with a 7-day free trial
Subscribe to TMT Breakout to keep reading this post and get 7 days of free access to the full post archives.